{
    "2020-07-28": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novo, Roche Scored Highest Returns on Invested Capital",
                "features": {
                    "keywords": [
                        "Novo",
                        "Roche",
                        "Highest Returns",
                        "Invested Capital"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Why the Earnings Surprise Streak Could Continue for AbbVie (ABBV)",
                "features": {
                    "keywords": [
                        "Earnings Surprise",
                        "Streak",
                        "AbbVie",
                        "ABBV"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q2 Earnings?",
                "features": {
                    "keywords": [
                        "Humira",
                        "Cancer Drugs",
                        "AbbVie",
                        "Q2 Earnings"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Third Pivotal Phase 3 Study Shows RINVOQâ„¢ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients",
                "features": {
                    "keywords": [
                        "Phase 3 Study",
                        "RINVOQ",
                        "upadacitinib",
                        "Topical Corticosteroids",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}